Alpha Cognition Inc
ACOG
Ранг среди акций
#20103
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Цена акции
$8.66
Рыночная капитализация
$134.42M
Изменение (1 день)
1.82%
Изменение (1 год)
72.07%
Страна
US
Торговля Alpha Cognition Inc (ACOG)
Категория
Healthcare
Коэффициент P/B для Alpha Cognition Inc (ACOG)
Коэффициент P/B на October 2026 TTM: -114.63
Согласно последним финансовым отчетам и цене акций Alpha Cognition Inc, текущий коэффициент P/B (TTM) составляет -114.63. В конце 2022 он составлял -274.94.
История P/B для Alpha Cognition Inc с 2018 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| 2026 (TTM) | -114.63 | -53.90% |
| 2023 | -248.67 | -9.55% |
| 2022 | -274.94 | -288.08% |
| 2021 | 146.19 | -97.93% |
| 2020 | 7.05K | 6,164.26% |
| 2019 | 112.47 | 16.25% |
| 2018 | 96.75 | 0.00% |
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 6.251 | -105.45% |
US
|
|
| 13.2547 | -111.56% |
US
|
|
| 4.208 | -103.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -105.39% |
NL
|
